Glypican-3 expression is silenced in human breast cancer

Glypican-3 (GPC3) is a membrane-bound heparan sulfate proteoglycan that is mutated in the Simpson-Golabi-Behmel syndrome. This is an X-linked condition characterized by overgrowth, and various visceral and skeletal dysmorphisms. The phenotype of the Simpson-Golabi-Behmel syndrome patients and GPC3-deficient mice, as well as gene transfection experiments indicate that GPC3 can act as an inhibitor of cell proliferation and survival. It has been previously shown that GPC3 expression is downregulated in mesotheliomas and ovarian cancer. Here we report that GPC3 expression is also silenced in human breast cancer, and that this silencing is due, at least in part, to hypermethylation of the GPC3 promoter. Ectopic expression of GPC3 inhibited growth in eight out of 10 breast cancer cell lines. Collectively, these data suggest that GPC3 can act as a negative regulator of breast cancer growth.

[1]  J. Allanson,et al.  Simpson-Golabi-Behmel syndrome associated with renal dysplasia and embryonal tumor: localization of the gene to Xqcen-q21. , 1992, American journal of medical genetics.

[2]  M. Golabi,et al.  A new X-linked mental retardation-overgrowth syndrome. , 1984, American journal of medical genetics.

[3]  C. McKerlie,et al.  Glypican-3–Deficient Mice Exhibit Developmental Overgrowth and Some of the Abnormalities Typical of Simpson-Golabi-Behmel Syndrome , 1999, The Journal of cell biology.

[4]  D. Schlessinger,et al.  Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome , 1996, Nature Genetics.

[5]  M. Götte,et al.  Functions of cell surface heparan sulfate proteoglycans. , 1999, Annual review of biochemistry.

[6]  J. Bodurtha,et al.  Report of another family with Simpson-Golabi-Behmel syndrome and a review of the literature. , 1992, American journal of medical genetics.

[7]  M. D'Esposito,et al.  DNA methylation in transcriptional repression of two differentially expressed X-linked genes, GPC3 and SYBL1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Neri,et al.  Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. , 1998, American journal of medical genetics.

[9]  S. Jhanwar,et al.  Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma , 2000, Oncogene.

[10]  W. Skarnes,et al.  glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. , 2000, Developmental biology.

[11]  D. Schlessinger,et al.  Frequent silencing of the GPC3 gene in ovarian cancer cell lines. , 1999, Cancer research.

[12]  N. Rosenblum,et al.  Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. , 2001, Developmental biology.

[13]  J. Filmus,et al.  Glypicans in growth control and cancer. , 2001, Glycobiology.

[14]  J. Testa,et al.  OCI-5/GPC3, a Glypican Encoded by a Gene That Is Mutated in the Simpson-Golabi-Behmel Overgrowth Syndrome, Induces Apoptosis in a Cell Line–specific Manner , 1998, The Journal of cell biology.

[15]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[16]  Qiong Shen,et al.  Isolation of complementary DNA encoding K-cadherin, a novel rat cadherin preferentially expressed in fetal kidney and kidney carcinoma. , 1994, Cancer research.

[17]  D. Schlessinger,et al.  Simpson-Golabi-Behmel syndrome: genotype/phenotype analysis of 18 affected males from 7 unrelated families. , 1996, American journal of medical genetics.